223 related articles for article (PubMed ID: 23892798)
41. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
42. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
43. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
44. C3 glomerulopathies. A new perspective on glomerular diseases.
Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M
Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752
[TBL] [Abstract][Full Text] [Related]
45. Proliferative Glomerulonephritis With Fibrils, Monoclonal κ Light Chain, and C3 Deposits.
Steinberg AG; Fox LC; Bender S; Batrouney A; Juneja S; Sirac C; Touchard G; Blombery P; Finlay MJ; Bridoux F; Barbour TD
Am J Kidney Dis; 2021 Sep; 78(3):459-463. PubMed ID: 33774080
[TBL] [Abstract][Full Text] [Related]
46. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
Ankawi GA; Clark WF
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28798244
[TBL] [Abstract][Full Text] [Related]
47. Morphologic variations of dense deposit disease: light and electron microscopic, immunohistochemical and clinical findings in 10 patients.
Joh K; Aizawa S; Matsuyama N; Yamaguchi Y; Kitajima T; Sakai O; Mochizuki H; Usui N; Hamaguchi K; Mitarai T
Acta Pathol Jpn; 1993 Oct; 43(10):552-65. PubMed ID: 8291443
[TBL] [Abstract][Full Text] [Related]
48. Membranoproliferative glomerulonephritis in Russian population.
Dobronravov VA; Smirnov AV
Ter Arkh; 2018 Dec; 90(12):39-47. PubMed ID: 30701832
[TBL] [Abstract][Full Text] [Related]
49. De novo C3 glomerulonephritis in a renal allograft.
Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
[TBL] [Abstract][Full Text] [Related]
50. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
51. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
52. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
53. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature.
Ahmed MS; Wong CF; Shawki H; Kapoor N; Pandya BK
Clin Nephrol; 2008 Apr; 69(4):298-301. PubMed ID: 18397706
[TBL] [Abstract][Full Text] [Related]
54. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.
Besbas N; Gulhan B; Gucer S; Korkmaz E; Ozaltin F
J Nephrol; 2014 Aug; 27(4):457-60. PubMed ID: 24536001
[TBL] [Abstract][Full Text] [Related]
55. [The course and prognosis of mesangioproliferative glomerulonephritis].
Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
[TBL] [Abstract][Full Text] [Related]
56. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
57. Remission of resistant MPGN type I with mycophenolate mofetil and steroids.
De S; Al-Nabhani D; Thorner P; Cattran D; Piscione TD; Licht C
Pediatr Nephrol; 2009 Mar; 24(3):597-600. PubMed ID: 18972137
[TBL] [Abstract][Full Text] [Related]
58. C4d as a Diagnostic Tool in Proliferative GN.
Sethi S; Nasr SH; De Vriese AS; Fervenza FC
J Am Soc Nephrol; 2015 Nov; 26(11):2852-9. PubMed ID: 25991041
[TBL] [Abstract][Full Text] [Related]
59. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
Khandelwal P; Bhardwaj S; Singh G; Sinha A; Hari P; Bagga A
Pediatr Nephrol; 2021 Mar; 36(3):591-600. PubMed ID: 32886193
[TBL] [Abstract][Full Text] [Related]
60. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]